Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2013 Second Quarter Earnings
October 01 2012 - 8:00AM
Business Wire
Forest Laboratories, Inc. (NYSE: FRX), an international
manufacturer and marketer of pharmaceutical products, will release
its Fiscal 2013 Second Quarter financial results before the U.S.
stock market opens on Tuesday, October 16, 2012. At 10:00 AM EDT,
Forest will host a conference call where Elaine Hochberg, Executive
Vice President, Sales & Marketing and Chief Commercial Officer,
Frank Perier, Executive Vice President Finance & Administration
and Chief Financial Officer, and Dr. Marco Taglietti, Senior Vice
President Research & Development and President, Forest Research
Institute, will discuss the financial results and relevant company
and industry topics. The conference call will be webcast live
beginning at 10:00 AM EDT on the Company's website www.frx.com and
also on the website www.streetevents.com. Please log on to either
website at least fifteen minutes prior to the conference call as it
may be necessary to download software to access the call. A replay
of the conference call will be available until November 16, 2012 at
both websites and also by dialing 1-855-859-2056 (US and Canada) or
+1-404-537-3406 (international), Conference Call ID # 33378270.
About Forest
Laboratories
Forest Laboratories’ (NYSE: FRX) longstanding global
partnerships and track record developing and marketing
pharmaceutical products in the United States have yielded its
well-established central nervous system and cardiovascular
franchises and innovations in anti-infective, respiratory,
gastrointestinal, and pain management medicine. The Company’s
pipeline, the most robust in its history, includes product
candidates in all stages of development across a wide range of
therapeutic areas. The Company is headquartered in New York, NY. To
learn more, visit www.FRX.com.
Except for the historical information contained herein, this
release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995. These
statements involve a number of risks and uncertainties, including
the difficulty of predicting FDA approvals, the acceptance and
demand for new pharmaceutical products, the impact of competitive
products and pricing, the timely development and launch of new
products, and the risk factors listed from time to time in Forest
Laboratories’ Annual Reports on Form 10-K, Quarterly Reports on
Form 10-Q, and any subsequent SEC filings. Forest assumes no
obligation to update forward-looking statements contained in this
rerelease to reflect new information or future events or
developments.
Forest Road Acquisition (NYSE:FRX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Forest Road Acquisition (NYSE:FRX)
Historical Stock Chart
From Jul 2023 to Jul 2024